Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLANCE: Natalizumab + Glatiramer Acetate in RRMS
NCT00097760Phase 2Completed
- Sponsor
- Biogen
- Start
- Jun 2003
- Primary completion
- Mar 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Natalizumab + GA with Placebo + GA (2 arms). Primary endpoint: Rate of development of new active lesions on MRI scans at 20 weeks. Started Jun 2003; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00097760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097760.